Moffitt logo

HURRICANE IAN UPDATE: All Moffitt Cancer Center appointments are canceled through Friday, Sept. 30. Get the latest information

Clinical Trials Search

Clinical Trial 22083

Cancer Type: Multiple Myeloma
Study Type: Other
NCT#:

Phase: N/A
Principal Investigator: Oswald, Laura

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

Real-World Clinical and Patient-Reported Outcomes Among Patients With Relapsed/Refractory Multiple Myeloma treated With Commercial CAR-T Therapy

Summary

To date, little is known about the real-world clinical outcomes or PROs among Relapsed/Refractory Multiple Myeloma patients treated with SOC ide-cel and cilta-cel. This study will address this important gap in knowledge

Objective

Aim 1: Describe real-world clinical outcomes (i.e., treatment response rates, incidence and severity of immune-mediated toxicities, progression-free and overall survival) among RRMM patients treated with SOC ide-cel and cilta-cel CAR-T therapy. Aim 2: Describe real-world PROs (i.e., HRQOL, symptom burden) among RRMM patients treated with SOC ide-cel and cilta-cel CAR-T therapy. Aim 3: Explore differences in clinical outcomes and PROs between RRMM patients treated with SOC ide-cel and cilta-cel CAR-T therapy

Treatments

Therapies

Medications

Inclusion Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Relapsed/Refractory Multiple Myeloma patients treated with standard of care ide-cel and cita-cel at Moffit
  • Able to speak and read English or Spanish
  • No documented or observable psychiatric or neurologic diagnoses that could interfere with participation (e.g., dementia, active psychosis)
  • Able to complete surveys on a smartphone, tablet, or computer with stable internet access
  • Able to provide informed consent

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.